𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics and safety of propiverine in patients with fatty liver disease

✍ Scribed by M. Siepmann; A. Nokhodian; D. Thümmler; W. Kirch

Publisher
Springer
Year
1998
Tongue
English
Weight
126 KB
Volume
54
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of isradipine in patien
Pharmacokinetics of isradipine in patients with chronic liver disease
✍ J. Cotting; J. Reichen; K. Kutz; R. Laplanche; E. Nüesch 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 523 KB

The pharmacokinetics of the dihydropyridine calcium antagonist isradipine has been examined in 8 healthy volunteers, 7 patients with non-cirrhotic chronic liver disease (CLD), and 8 patients with biopsy-proven cirrhosis (CIR). Isradipine was simultaneously given orally (12C 5 mg) and i.v. (13C 1 mg)

Safety and immunogenicity of hepatitis A
Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease
✍ Emmet B. Keeffe; Sten Iwarson; Brian J. McMahon; Karen L. Lindsay; Raymond S. Ko 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

Acute hepatitis A superimposed on chronic liver disease (CLD) has been associated with severe or fulminant hepatitis. An open, multicenter study was performed to compare the safety and immunogenicity of an inactivated hepatitis A vaccine in patients with CLD with that in healthy subjects. A secondar